Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act.
Advances in highly active antiretroviral therapy (HAART) options for people living with HIV/AIDS have resulted in decreased morbidity and mortality. To some extent, the role of disease progression in eroding quality of life (QOL) erosion in the pre-HAART age is now supplanted by drug toxicities, one of the Achilles' heels of HAART. This article reviews research findings on treatment and QOL outcomes a decade into the HAART era.
Burgoyne
Robert W
RW
Immunodeficiency Clinic, University Health Network, University of Toronto, 200 Elizabeth Street, Toronto, Canada M5G 2C4. bob.burgoyne@uhn.on.ca
Tan
Darrell H S
DH
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods*; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000503:physiopathology; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008020:Life Support Care / Q000379:methods* / Q000639:trends; D011788:Quality of Life